Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT: NCT05934526 · COMPLETED

NCT IDNCT05934526
StatusCOMPLETED
Start Date2023-12-28
Completion2025-12-22

Brief Summary

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

Frequently Asked Questions

What is Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)?

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) is a clinical trial registered under NCT05934526. Current status: COMPLETED.

What is the status of NCT05934526?

The current status of NCT05934526 (Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)) is: COMPLETED.

When did Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) start?

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) started on 2023-12-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑